Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04666961
Other study ID # ICO-2020-06
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 3, 2021
Est. completion date August 1, 2033

Study information

Verified date April 2022
Source Institut Cancerologie de l'Ouest
Contact Victoire BRILLAUD-MEFLAH, MD
Phone 0240679818
Email Victoire.brillaud-meflah@ico.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications. This mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients. Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy. Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence. The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant hormone therapy on the surgical management of extensive DCIS.


Description:

Description of the modalities for recruiting : Following screening and discovery of a DCIS, patients are referred to the center for surgical management. During a standard consultation, the surgeon presents the study to the patient who has been diagnosed with extensive DCIS with an indication for mastectomy. The surgeon provides the patient with the information note and the consent form to participate in the study. Once the consent form is signed by the patient and the investigator, the investigator prescribes a screening test to be performed within 30 days prior to the start of hormone therapy. Screening assessment includes : A clinical exam and a breast imaging exam (mammography and breast and axillary ultrasound). In case of a suspicious breast ultrasound image, microbiopsy will be performed to eliminate an infiltrating component. One or more macrobiopsy. Each biopsied site will be located using an X-ray clip inserted at the time of sample. A MRI post-macrobiopsy. Research of estrogen receptor expression Once the investigator has verified and validated all the eligibility criteria, the patient will be included. Prescriptions for Tamoxifen (non-menopausal patients) or Anastrozole (menopausal patients) are given to patients and dispensed by the center's pharmacy. Monitoring during treatment : Patients will benefit from imaging monitoring (Mammography, +/- breast ultrasound, +/- axillary ultrasound, MRI) at 3 months and 6 months during hormonotherapy. In case of progression observed during treatment, hormone therapy will be stopped and you will then benefit from a mastectomy. Surgery : Mastectomy or tumorectomy will be performed according to the tumor response to hormone therapy observed on MRI. All patients will benefit sentinel node detection. An additional axillary dissection will be performed based on the results of the sentinel node analysis. Analysis of biomarkers and tumor microenvironment before and after treatment on diagnostic macrobiopsies and on tumorectomy or mastectomy will be performed at Institut de Cancérologie de l'Ouest. Patients will be seen in postoperative consultation. Adjuvant treatments or re-surgical interventions will be prescribed, carried out, and the patients will be followed up and examined at 6 months after surgery or at the end of adjuvant treatments and then annually for 10 years (with control mammography). Patients who have had conservative surgery will have an MRI at 6 months from the end of radiotherapy. All patients will be asked to complete quality of life questionnaires at baseline, 6 and 12 months post-surgery, and annually for 9 years: EORTC QLQ-C30 (up to 5 years only), Short Form (36) Health Survey questionnaire.


Recruitment information / eligibility

Status Recruiting
Enrollment 262
Est. completion date August 1, 2033
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Patient = 40 years old 2. Histological diagnosis of ductal carcinoma in situ without infiltrating contingent 3. Clinical T0N0 4. Estrogen receptor positive (OR+) regardless of progesterone receptor (PR) status 5. Indication for mastectomy 6. DCIS visible on MRI performed with clip sequence 7. Effective contraceptive method for women of childbearing age who are sexually active and who have reported sexual activity. 8. Informing the patient and obtaining free, informed and written consent signed by the patient and the investigator. 9. Affiliated patient or beneficiary of the social security system. Exclusion Criteria: 1. Invasive breast carcinoma 2. Lobular carcinoma in situ 3. pN+ patient 4. Indication for conservative surgery 5. Contraindications to anastrozole or tamoxifen 6. Concomitant treatments that may interact and reduce the efficacy of tamoxifen by interaction with cytochrome CYP2D6. 7. Histologically proven multifocal lesion 8. Contraindication to breast MRI (pace maker, heart valve, metallic implant, neuronal or peripheral stimulator, severe claustrophobia, ...) 9. History of homolateral breast cancer 10. Ongoing contralateral breast cancer 11. Known mutation BRCA1 BRCA2 12. Other cancer in progress at inclusion 13. Pregnant woman, or breastfeeding, 14. Persons deprived of liberty or under guardianship or trusteeship, 15. Impossibility to undergo the medical follow-up of the trial for geographical, social, psychic or psychiatric reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tamoxifen 20 mg
Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
Anastrozole 1Mg Tab
Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.

Locations

Country Name City State
France ICO - Site Paul Papin Angers
France Institut Bergonie Bordeaux
France Institut de cancérologie de Montpellier Montpellier
France Centre Antoine Lacassagne Nice
France Hopital Saint Joseph Paris
France Institut Curie - Site de Paris Paris
France Institut de Cancérologie de l'Ouest Saint Herblain
France IUCT-O Toulouse

Sponsors (1)

Lead Sponsor Collaborator
Institut Cancerologie de l'Ouest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of neoadjuvant hormonotherapy % of conservative surgeries performed after hormonotherapy 6 months of hormonotherapy
Secondary Disease-free survival (DFS) DFS rates at 5 and 10 years post-surgery 5 and 10 years post-surgery
Secondary Overall survival (OS) Survival rates at 5 and 10 years post-surgery 5 and 10 years post-surgery
Secondary Pathologic Complete Response (pCR) Pathologic complete response is defined as no residual invasive cancer in the surgical specimen 6 months of hormonotherapy
Secondary Predictive factors of response Response is defined by the variation in the diameter of the longest dimension of the target lesion measured by MRI 3 and 6 months of hormonotherapy
Secondary Quality of Life (Qol) EORTC QLQ-C30 questionnaire At baseline, at 6 months and 12 months post-surgery, and then each year for 4 years
Secondary Quality of Life (Qol) SF-36 questionnaire At baseline, at 6 months and 12 months post-surgery, and then each year for 9 years
See also
  Status Clinical Trial Phase
Completed NCT03618433 - KİNECT® - Video Games Based Physiotherapy Programme in Patients With Breast Cancer Surgery N/A
Terminated NCT05395936 - Mastectomy Flap Temperature Study N/A
Recruiting NCT03757793 - Near-infrared Spectroscopy for Monitoring Tissue Oxygenation in Breast Reconstruction
Completed NCT01781299 - Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU Phase 4
Completed NCT01176786 - Reusable Versus Disposable Draping System in Breast Reconstruction Surgery N/A
Terminated NCT00616824 - The Use of an Acellular Dermal Matrix in a Two-Staged Breast Reconstruction Phase 4
Recruiting NCT06033456 - Combining Stellate Ganglion and T2 and T3 Radiofrequency Ablation on Post-mastectomy Complex Regional Pain Syndrome N/A
Recruiting NCT05975359 - Assessment of the Interi Manifold in Implant-Based Breast Reconstruction N/A
Withdrawn NCT03135392 - Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer N/A
Recruiting NCT01217593 - Ultrasound vs. Predetermined Distance Techniques for Paravertebral Nerve Block in Patients Having Breast Surgery N/A
Completed NCT01231204 - Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks Phase 4
Recruiting NCT05069805 - Comparison of Erector Spinae Plane Block and Pectoral Nerve Block for Acute and Chronic Pain in Mastectomies N/A
Completed NCT01687348 - Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy Phase 3
Completed NCT00555503 - Registry of Mastectomy for Breast Cancer Risk Reduction N/A
Recruiting NCT03598712 - Local Compression Seroma DIminution Objective (CLODIS) Phase 3
Not yet recruiting NCT04457167 - Mastectomy With Retention of the Nipple-areola Complex, Robot-assisted or Not, and / or Immediate or Seconday Reconstruction by Latissimus Dorsi Flap, Robot-assisted or Not. N/A
Recruiting NCT05494502 - Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients N/A
Recruiting NCT02894021 - PREvention of Post-mastectomy LYMphoceles by PAdding N/A
Recruiting NCT04891510 - A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery N/A
Enrolling by invitation NCT05658367 - Effect of Aromatherapy Massage on Pain and Anxiety After Mastectomy N/A